Literature DB >> 16410313

2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells.

Sebastian Stark1, Carsten Watzl.   

Abstract

The recently described family of SLAM-related receptors plays an important role in the modulation of lymphocyte activity. The members of this family expressed on human NK cells are 2B4 (CD244), NTB-A and CRACC (CS1). The ligands of these surface receptors are also present on all human NK cells, suggesting that 2B4, NTB-A and CRACC are engaged during the contact of neighboring NK cells. Here we investigate the functional consequence of this interaction. We show that blocking the engagement of 2B4, NTB-A and CRACC has no effect on the proliferation or the development of the cytotoxic potential of human NK cells. However, triggering of 2B4, NTB-A or CRACC by their physiological ligands on MHC class I-negative target cells induces potent NK cell cytotoxicity. This suggests that the engagement of inhibitory receptors by MHC class I on neighboring NK cells blocks 2B4-, NTB-A- and CRACC-induced NK cell cytotoxicity, thereby ensuring that NK cells do not kill each other. In support of this, limiting inhibitory receptor engagement by antibodies leads to the autologous killing of NK cells in a 2B4-, NTB-A- and CRACC-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410313     DOI: 10.1093/intimm/dxh358

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  17 in total

Review 1.  Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Tim Luetkens; Djordje Atanackovic
Journal:  Oncoimmunology       Date:  2017-03-28       Impact factor: 8.110

2.  Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function.

Authors:  Mario-Ernesto Cruz-Munoz; Zhongjun Dong; Xiaochu Shi; Shaohua Zhang; André Veillette
Journal:  Nat Immunol       Date:  2009-01-18       Impact factor: 25.606

3.  Homotypic cell to cell cross-talk among human natural killer cells reveals differential and overlapping roles of 2B4 and CD2.

Authors:  Eun-Ok Kim; Tae-Jin Kim; Nayoung Kim; Sung Tae Kim; Vinay Kumar; Kyung-Mi Lee
Journal:  J Biol Chem       Date:  2010-09-02       Impact factor: 5.157

4.  Alternative splicing and mRNA expression analysis of bovine SLAMF7 gene in healthy and mastitis mammary tissues.

Authors:  Zhihua Ju; Changfa Wang; Qiuling Li; Minghai Hou; Shuai Gao; Qinlei Hou; Jianbin Li; Jinming Huang; Jifeng Zhong
Journal:  Mol Biol Rep       Date:  2011-07-17       Impact factor: 2.316

5.  Increased expression of peripheral blood leukocyte genes implicate CD14+ tissue macrophages in cellular intestine allograft rejection.

Authors:  Chethan Ashokkumar; Mylarappa Ningappa; Sarangarajan Ranganathan; Brandon W Higgs; Qing Sun; Lori Schmitt; Sara Snyder; Jennifer Dobberstein; Maria Branca; Ronald Jaffe; Adriana Zeevi; Robert Squires; Feras Alissa; Benjamin Shneider; Kyle Soltys; Geoffrey Bond; Kareem Abu-Elmagd; Abhinav Humar; George Mazariegos; Hakon Hakonarson; Rakesh Sindhi
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

Review 6.  X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses.

Authors:  Hamid Bassiri; W C Janice Yeo; Jennifer Rothman; Gary A Koretzky; Kim E Nichols
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 7.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

8.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Authors:  Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter Burger; Alfred I Lee; Klaus Podar; Teru Hideshima; Audie G Rice; Anne van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Journal:  Blood       Date:  2007-09-28       Impact factor: 22.113

9.  Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

Authors:  Shauna M Collins; Courtney E Bakan; Gina D Swartzel; Craig C Hofmeister; Yvonne A Efebera; Hakju Kwon; Gary C Starling; David Ciarlariello; Shakthi Bhaskar; Edward L Briercheck; Tiffany Hughes; Jianhua Yu; Audie Rice; Don M Benson
Journal:  Cancer Immunol Immunother       Date:  2013-10-26       Impact factor: 6.968

Review 10.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.